Evidence map›Paper›PMID 24052632›Full record

ReviewJournal of the American Society of Nephrology : JASN2013

Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

Jérôme Tourret, Gilbert Deray, Corinne Isnard-Bagnis

3 registry-linked trialsOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the American Society of Nephrology : JASN, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 76 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02457494 completednot on this mapstarted 2015, after this paper: background citation

CALVIH: Determination of Kidney Stone Risk Factors in Patients Infected With HIV

TypeobservationalSponsorCorinne Isnard BagnisRan2015 to 2018Enrolled23ConditionsNephrolithiasis, HIV
NCT02588287 nacompletednot on this mapstarted 2015, after this paper: background citation

Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir

TypeinterventionalSponsorUniversity of Colorado, DenverRan2015 to 2016Enrolled14ConditionsHepatitis C and HIV CoinfectionArmsBlood draws for tenofovir PK, renal function
NCT03126370 phase4completednot on this mapstarted 2018, after this paper: background citation

Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.

TypeinterventionalSponsorUniversity of Colorado, DenverRan2018 to 2019Enrolled10ConditionsHepatitis C, HIV CoinfectionArmsTDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Jérôme TourretNephrology Department, Groupe Hospitalo-Universitaire Pitié-Salpêtrière and Université Pierre et Marie Curie, Paris, France.
Gilbert Deray
Corinne Isnard-Bagnis
Sorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tenofovir disoproxil fumarate (TDF), the first nucleotidic inhibitor of HIV reverse transcription, became available in 2001. It has been extensively used worldwide and is now the most prescribed antiretroviral (ARV) drug. Its high antiviral activity and favorable metabolic profile are responsible for its success. Furthermore, TDF has been associated with other ARVs to form new combined antiretroviral treatments in only one tablet once-a-day, which increases treatment adherence. Fears of potential nephrotoxicity that tenofovir would have in common with two other drugs from the same family (adefovir, used to treat hepatitis B, and cidofovir, used to treat cytomegalovirus infections) were alleviated by the early clinical trials. Yet, in 2001, the first case of TDF-induced acute nephrotoxicity was published. Numerous cases have been published since then, and it is now established that TDF presents a tubular toxicity risk. Some facilitating factors have been identified, such as co-prescription of didanosine or boosted protease inhibitor, preexisting CKD, low body weight, and associated diabetes mellitus. Conversely, whether TDF is nephrotoxic in the long term is a highly debated question. Some studies suggest a decreased GFR when TDF is prescribed for a long period, while others indicate that TDF is safe for the kidneys even after many years of use. Here we review the differences in patient characteristics, study designs, and measured outcomes that can possibly explain these conflicting findings. We conclude with rational recommendation for appropriate TDF prescription.

Indexed as

AdenineAntirheumatic AgentsClinical Trials as TopicHIV InfectionsHumansIncidenceKidneyPhosphorous AcidsRenal InsufficiencyRisk Factors9-(2-((bis(pivaloyloxymethoxy)phosphinoyl)methoxy)propyl)adenineAdenineAntirheumatic AgentsPhosphorous Acids

Identifiers

PMID24052632
PMCPMC3785270
OpenAlexW2164719418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.